A lot of avoidable needless disease burden, especially as we enter the winter months. Boosters aren't just important for older adults, all ages benefit from being up to date on vaccination. And the new

Differences in death rates by vaccination status for people 50 and older. Get vaccinated! People that received two or more boosters had 14 times lower risk of dying from COVID than the unvaccinated. Even

The CDC director has signed off on approval as well. We now officially have four coronavirus vaccines in the US! About 26-37 million adults remain unvaccinated at this point. Risk of hospitalization and

It now goes to the CDC. The CDC's advisory committee ACIP will meet July 19th to discuss authorizing Novavax, and then the CDC director will sign off. Unfortunately it was only authorized as a primary

The CDC's ACIP is meeting Thursday to discuss it, and then it goes to the CDC director for final approval. This was based on an immunobridging trial showing non-inferior immune responses compared to an

ACIP unanimously approves preference for mRNA vaccines over J&J for all adults unless contraindicated in light of the new data update on Thrombosis with Thrombocytopenia Syndrome (TTS). The TTS risk

The coronavirus is more severe for children than the Flu, but even setting aside that there's reasons to vaccinate a subpopulation besides individual benefit. We routinely vaccinate kids against Flu mainly

A Biden Admin official is saying Pfizer is expected to apply for third dose boosters for all adults in the coming weeks. I think this will eventually be the case, just a matter of when. The FDA was fairly

No qualifications. 2 dose series for all kids (10 micrograms vs the adult 30 micrograms dose). It goes to Walensky who should greenlight vaccination for this group tonight or tomorrow. This meeting was

Walensky overruled ACIP's guidance and supported Pfizer boosters for those in occupations/institutional settings at high risk of exposure to COVID. Originally this group failed in the ACIP vote 6-9. So

ACIP voted on guidance for Pfizer boosters today. A few surprises. A good example of how hard it is to decide appropriate vaccination policy with mixed and incomplete data and complex priorities. On the

ACIP didn't make a recommendation on J&J yesterday, but some useful background information was presented to contextualize things a bit more on the risks and costs. While 7.2 million doses of J&J

Abstract To move forward for future adoption, the community needs to improve just as much as the protocol. Some improvements don’t fit in an AIP as they are not purely protocol-based. There is a lot to